義大醫院胃腸肝膽科及內視鏡科醫師介紹 

義大醫院胃腸肝膽科 兼任主治醫師


專長

治療性內視鏡術、大腸癌、大腸息肉症、逆流性食道炎、巴瑞氏食道、消化道潰瘍、消化道出血、胃癌、超音波學、慢性B型及C型肝炎、肝腫瘤、 膽道胰臟疾病、生活品質之量測、幽門桿菌之治療、消化道微菌細菌學


張吉仰

學經歷

輔大附設醫院副院長
教育部部定副教授
前義大醫院胃腸肝膽科、內視鏡科、一般醫學科主任
台大醫院內科兼任主治醫師
台灣大學醫學博士
台大醫學系畢業
日本國家癌病中心內視鏡研修
美國內視鏡學會會員
台灣消化系醫學會副祕書長
台灣消化內視鏡醫學會執行副祕書長
台灣消化內視鏡醫學會IEE group召集人
台灣消化系醫學會專科指導醫師
台灣消化內視鏡醫學會專科指導醫師

論文

1. Chang CY, Chang YT, Lee PL, Lin JT.
Tracheoesophageal fistula. Gastrointest Endosc 2004;59:870.

2. Chang CY, Wang HP, Mao TL, Hu RH, Yang PM, Lai MY, Lin JT.
Unusual sonographic appearance of a gastrointestinal stromal tumor presenting as a large multilocular cystic mass. J Clin Ultrasound 2004;32:200-3.

3. Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, Lin JT.
Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology 2006;53:1-4.

4.Chang CY, Yang PM, Hung SP, Tsay W, Lin LC, Lin JT, Wang HP.
Cavernoustransformation of the portal vein: etiology determines the outcome.Hepatogastroenterology 2006;53:892-7.

5.Liao WC, Wang HP, Chiu HM, Chang CY, Lin JT.
Multiple hepatic nodules:raremanifestationofclonorchiasis.JGastroenterolHepatol2006;21:1497-500.

6.Chiang TH, Chang CY, Huang KW, Liou JM, Lin JT, Wang HP.
Jejunojejunalintussusception secondary to a jejunal lipoma in an adult. J GastroenterolHepatol 2006;21:924-6.

7.Lee TC, Chang CY, Lin JT, Wang HP.
An easily overlooked bleeder mirroredon transjejunostomy retrograde endoscopy. Dig Liver Dis 2006;38:527-8.

8.Lin CK, Chiu HM, Lien WC, Liu YP, Chang CY, Wang HP.
Ultrasonographicbisection approximation method for gastrointestinal obstruction in ER.Hepatogastroenterology 2006;53:547-51.

9.Chiu HM, Chang CY, Chen CC, Lee YC, Wu MS, Lin JT, Shun CT, Wang HP.
A prospective comparative study of narrow-band imaging, chromoendoscopy,and conventional colonoscopy in the diagnosis of colorectal neoplasia. Gut2007;56:373-9.

10.Chang CY, Tu CH, Chiang TS, Wang HP.
Acute gastric ulcer associated withgamma knife treatment (conformal stereotactic radiotherapy) of recurrenthepatocellular carcinoma. Endoscopy 2007;39 Suppl 1:E154.

11.Tai CM, Huang SP, Wang HP, Lee TC, Chang CY, Tu CH, Lee CT, Chiang TH,Lin JT, Wu MS.
High-risk ED patients with nonvariceal upper gastrointestinalhemorrhage undergoing emergency or urgent endoscopy: a retrospectiveanalysis. Am J Emerg Med 2007;25:273-8.

12.Tu CH, Tai CM, Chang CY, Chiang TH, Lee CT, Lin JT.
Diffuse esophagealparakeratosis. Endoscopy 2007;39 Suppl 1:E119-20.

13.Lee TC, Huang SP, Yang JY, Chang CY, Liou JM, Liu CH, Huang MS, WangHP.
Age is not a discriminating factor for outcomes of therapeutic uppergastrointestinal endoscopy. Hepatogastroenterology 2007;54:1319-22.

14.Chang CY, Lee YC, Lee CT, Tu CH, Hwang JC, Chiang H, Tai CM, ChiangTH, Wu MS, Lin JT.
The application of Prague C and M criteria in thediagnosis of Barrett's esophagus in an ethnic Chinese population. Am JGastroenterol 2009;104:13-20.

15.Tai CM, Lee YC, Wu MS, Chang CY, Lee CT, Huang CK, Kuo HC, Lin JT.
The Effect of Roux-en-Y Gastric Bypass on Gastroesophageal Reflux Diseasein Morbidly Obese Chinese Patients. Obes Surg 2009;19:565-70.

16.Chang CY, Hung CK, Chang YY, Tai CM, Lin JT, Wang JD.
Health-relatedQuality of Life in Adult Patients with Morbid Obesity Coming for BariatricSurgery. Obes Surg 2010; 20(8):1121-7.

17.Chang CY, Huang CK, Chang YY, Tai CM, Lin JT, Wang JD.
Cross-Validation of the Taiwan Version of the Moorehead-Ardelt Quality ofLife Questionnaire II with WHOQOL and SF-36. Obes Surg2010;20(11):1568-74

18.Wei YF, Wu HD, Chang CY, Huang CK, Tai CM, Hung CM, Tseng WK, WuCC.
The Impact of Various Anthropometric Measurements of Obesity onPulmonary Function in Candidates for Surgery. Obes Surg.2010;20(5):589-94.

19.Chang CY, Chiu HM, Wang HP, Lee CT, Tai JJ, Tu CH, Tai CM, Chiang TH,Huang JK, Chang DC, Lin JT.
An endoscopic training model to improveaccuracy of colonic polyp size measurement. Int J Colorectal Dis2010May;25(5):655-60

20.Liou JM, Lin JT, Chang CY, Chen MJ, Cheng TY, Lee YC, Chen CC, ShengWH, Wang HP, Wu MS.
Levofloxacin-based and clarithromycin-based tripletherapies as first-line and second-line treatments for Helicobacter pyloriinfection:a randomized comparative trial with crossover design. Gut.2010;59(5):572-8.

21.Lee CT, Lee TL, Liao WC, Chang CY, Tai CM, Chiang TH, Tu CH, TsengWK, Lin JT.
Myocardial ischemia during endoscopic retrogradecholangiopancreatography- an overlooked issue with significant clinicalimpact. J Gastroenterol Hepatol. 2010; 25(9):1518-24

22.Lee CT, Chang CY, Lee YC, Tai CM, Wang WL, Tseng PH, Hwang JC,Hwang TZ, Wang CC, Lin JT.
Narrow-band imaging with magnifyingendoscopy for the screening of esophageal cancer in patients with primaryhead and neck cancers. Endoscopy. 2010; 42(8):613-9.

23.Wang WL, Lee CT, Lee YC, Hwang TZ, Wang CC, Hwang JC, Tai CM, ChangCY, Wang CP, Ko JY, Lin JT.
Risk factors for developing synchronousesophageal neoplasia in patients with head and neck cancer. Head &Neck.2011; 33(1):77-81.

24.Tai CM, Wang HP, Lee CT, Chang CY, Wang WL, Tseng CH, Lin JT.
Esophageal obstruction by a tangled nasogastric tube. 2010; 72(5):1057-8

25.Tai CM, Lee YC, Tu HP, Huang CK, Wu MT, Chang CY, Lee CT, Wu MS, LinJT, Wang WM.
The Relationship Between Visceral Adiposity and the Risk ofErosive Esophagitis in Severely Obese Chinese Patients. Obesity(SilverSpring). 2010; 18(11):2165-9

26.Liao WC, Lee CT, Chang CY, Leung JW, Chen JH, Tsai MC, Lin JT, Wu MS,Wang HP.
Randomized trial of 1-minute versus 5-minute endoscopic balloondilation for extraction of bile duct stones. Gastrointest Endosc2010;72(6):1154-62

27.Chang CY, Huang CK, Chang YY, Tai CM, Lin JT, Wang JD.
Prospectivestudy of health-related quality of life after Roux-en-Y bypass surgery formorbid obesity. Br J Surg 2010; 97:1541-1546

28.Chang CY, Cook MB., Lee YC, Lin JT, Ando T, Bhatia S, Chow WH,El-Omar EM, Goto H, Li YQ, McColl K, Rhee PL, Sharma P, Sung JJ, WongJY, Wu JC, Ho KY,
Current Status of Barrett’s Esophagus Research in Asia. JGastroenterol Hepatol. 2011;26(2):240-6.

29.Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, WangHP, Wu MS, Lin JT.
Empirical modified sequential therapy containinglevofloxacin and high-dose esomeprazole in second-line therapy forHelicobacter pylori infection: a multicentre clinical trial. J AntimicrobChemother. 2011; 66(8): 1847-52

30.Chang CY, Wu MS, Lee CT, Hwang JC, Tai CM, Perng DS, Lin CW, WangWL, Wang JD, Lin JT.
Prospective survey for the etiology and outcome ofpeptic ulcer bleeding: a community based study in Southern Taiwan. J FormosMed Assoc.2011;110(4):223-9

31.Liou JM, Chang CY, Sheng WH, Wang YC, Chen MJ, Lee YC, Hung HW,Chian H, Chang SC, Wu MS, Lin JT.
Genotypic resistance in Helicobacterpylori strains correlates with susceptibility test and treatment outcomes afterlevofloxacin- and clarithromycin-based therapies. Antimicrob AgentsChemother. 2011 ;55(3):1123-9.

32.Tai CM, Huang CK, Hwang JC, Chiang H, Chang CY, Lee CT, Yu ML, LinJT.
Improvement of nonalcoholic fatty liver disease after bariatric surgery inmorbidly obese Chinese patients. Obes Surg. 2012;22(7):1016-21

33.Wang WL, Chang WL, Yeh YC, Lee CT, Chang CY, Lin JT, Sheu BS.
Concomitantly elevated serum matrix metalloproteinases 3 and 9 can predictsurvival of synchronous squamous cell carcinoma of the upper aero-digestivetract. Mol Carcinog. 2013; 52(6):438-45.

34.Hsu YC, Mo LR, Chang CY, Perng DS, Tseng CH, Lo GH, Tai CM, Lin CW,Hsu CC, Hsu CY, Huang SC, Lin JT.
Entecavir versus lamivudine in thetreatment of chronic hepatitis B patients with hepatic decompensation. AntivirTher. 2012;17(4):605-12

35.Lee CT, Chang CY, Tai CM, Wang WL, Tseng CH, Hwang JC, Lin JT.
Endoscopic submucosal dissection for early esophageal neoplasia: a singlecenter experience in South Taiwan. J Formos Med Assoc. 2012;111(3):132-9

36.Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ,Hsu YC, Tseng CH, Tseng PH, Chang L, Chang WH, Wang HP, Shun CT,Wu JY, Lee YC, Lin JT, Wu MS; on behalf of the Taiwan HelicobacterConsortium.
Efficacy of genotypic resistance-guided sequential therapy in thethird-line treatment of refractory Helicobacter pylori infection: a multicentreclinical trial. J Antimicrob Chemother. 2013; 68(2):450-456

37.Hsu YC, Wu CY, Chang CY, Tai CM, Tseng CH, Perng DS, Mo LR, Lin JT.
Pretreatment viral DNA stratifies mortality risk in patients receiving antiviraltherapy for severe acute exacerbation of chronic hepatitis B. Antivir Ther.2013;18(2):221-8.

38.Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ,Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC,Shun CT, Lin JT, Lee YC, Wu MS;
Taiwan Helicobacter Consortium.Sequential versus triple therapy for the first-line treatment of Helicobacterpylori: a multicentre, open-label, randomised trial. Lancet.2013;381(9862):205-13

39.Lin CW, Lin CC, Mo LR, Chang CY, Perng DS, Hsu CC, Lo GH, Chen YS,Yen YC, Hu JT, Yu ML, Lee PH, Lin JT, Yang SS.
Heavy alcoholconsumption increases the incidence of hepatocellular carcinoma in hepatitisB virus-related cirrhosis. J Hepatol. 2013 Apr;58(4):730-5.

40.Tai CM, Huang CK, Lee YC, Chang CY, Lee CT, Lin JT.
Increase ingastroesophageal reflux disease symptoms and erosive esophagitis 1 year afterlaparoscopic sleeve gastrectomy among obese adults. 2013; 27(4):1260-6.

41.Lo GH, Perng DS, Chang CY, Tai CM, Wang HM, Lin HC.
Controlled trial ofligation plus vasoconstrictor versus proton pump inhibitor in the control ofacute esophageal variceal bleeding. J Gastroenterol Hepatol.2013;28(4):684-9.

42.Wang WL, Wang CP, Wang HP, Lee CT, Chang CY, Tai CM, Tseng CH,Hwang TZ, Wang CC, Lo JL, Tseng PH, Chiu HM, Lee JM, Ko JY, Lou PJ,Wu MS, Lee YC, Lin JT.
The benefit of pretreatment esophageal screeningwith image-enhanced endoscopy on the survival of patients withhypopharyngeal cancer. Oral Oncol. 2013;49(8):808-13

43.Tai CM, Lin HY, Yen YC, Huang CK, Hsu WL, Huang YW, Chang CY, WangHP, Mo LR.
Effectiveness of intragastric balloon treatment for obese patients:one-year follow-up after balloon removal. Obes Surg. 2013;23(12):2068-74.

44.Lo GH, Lin CW, Perng DS, Chang CY, Lee CT, Hsu CY, Wang HM, Lin HC.
A retrospective comparative study of histoacryl injection and banding ligationin the treatment of acute type1 gastric variceal hemorrhage. Scand JGastroenterol. 2013;48(10):1198-204.

45.Sugano K, Choi MG, Lin JT, Goto S, Okada Y, Kinoshita Y, Miwa H, ChiangCE, Chiba T, Hori M, Fukushima Y, Kim HS, Chang CY, Date M; on behalf ofthe LAVENDER Study Group.
Multinational, double-blind, randomised,placebo-controlled, prospective study of esomeprazole in the prevention ofrecurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDERstudy. Gut. 2014; 63(7):1061-8

46.Hsu YC, Wu CY, Lane HY, Chang CY, Tai CM, Tseng CH, Lo GH, Perng DS,Lin JT, Mo LR.
Determinants of hepatocellular carcinoma in cirrhotic patientstreated with nucleos(t)ide analogues for chronic hepatitis B. J AntimicrobChemother. 2014;69(7):1920-7

47.Tai CM, Huang CK, Tu HP, Hwang JC, Chang CY, Yu ML.
PNPLA3 genotypeincreases susceptibility of nonalcoholic steatohepatitis among obese patientswith nonalcoholic fatty liver disease. Surg Obes Relat Dis. 2015;11(4):888-94

48.Wang WL, Chang IW, Chang CY, Lin JT, Mo LR, Wang HP, Lee CT.
Circumferential balloon-based radiofrequency ablation for ultralong andextensive flat esophageal squamous neoplasia. Gastrointest Endosc.2014;80(6):1185-9.

49.Fang YJ, Liou JM, Chen CC, Lee JY, Hsu YC, Chen MJ, Tseng PH, Chen CC,Chang CY, Yang TH, Chang WH, Wu JY, Wang HP, Luo JC, Lin JT, ShunCT, Wu MS; for the Taiwan Gastrointestinal Disease and HelicobacterConsortium.
Distinct aetiopathogenesis in subgroups of functional dyspepsiaaccording to the Rome III criteria. Gut. 2014 (in press)

50.Wang WL, Wang YC, Lee CT, Chang CY, Lo JL, Kuo YH, Hsu YC, Mo LR.
The impact of human papillomavirus infection on the survival and treatmentresponse of patients with esophageal cancers. J Dig Dis. 2015;16(5):256-63

51.Liou JM, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Wu JY, Luo JC,Liou TC, Chang WH, Tseng CH, Wu CY, Yang TH, Chang CC, Wang HP,Sheu BS, Lin JT, Bair MJ, Wu MS; Taiwan Gastrointestinal Disease andHelicobacter Consortium.
The Primary Resistance of Helicobacter pylori inTaiwan after the National Policy to Restrict Antibiotic Consumption and ItsRelation to Virulence Factors-A Nationwide Study. PLoS One.2015;10(5):e0124199

52.Wang WL, Chang WL, Yang HB, Chang IW, Lee CT, Chang CY, Lin JT, SheuBS.
Quantification of tumor infiltrating Foxp3+ regulatory T cells enables theidentification of high-risk patients for developing synchronous cancers overupper aerodigestive tract. Oral Oncol. 2015;51(7):698-703.

53.Singh R, Jayanna M, Wong J, Lim LG, Zhang J, Lv J, Liu D, Lee YC, Han ML,Tseng PH, Namasivayam V, Banerjee R, Uedo N, Chan WK, Ho SH, Chen SY,Bhatia S, Funasaka K, Ando T, Wu J, Lesmana C, Tam W, Wang WL, ChangCY, Jung HY, Jung KW, Bestari MB, Yao K, Chong VH, Sharma P, Ho KY.
Narrow-band imaging and white-light endoscopy with optical magnification inthe diagnosis of dysplasia in Barrett's esophagus: results of the Asia-PacificBarrett's Consortium Endosc Int Open. 2015;3(1):E14-8

54.Wang WL, Chang IW, Chen CC, Chang CY, Mo LR, Lin JT, Wang HP, Lee CT.
Radiofrequency Ablation Versus Endoscopic Submucosal Dissection inTreating Large Early Esophageal Squamous Cell Neoplasia. Medicine(Baltimore). 2015 Dec;94(49):e2240.

55.Liou JM, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Yang TH,Luo JC, Wu JY, Liou TC, Chang WH, Hsu YC, Tseng CH, Chang CC, Bair MJ,Liu TY, Hsieh CF, Tsao FY, Shun CT, Lin JT, Lee YC, Wu MS; TaiwanGastrointestinal Disease and Helicobacter Consortium.
Sequential therapy for10 days versus triple therapy for 14 days in the eradication of Helicobacterpylori in the community and hospital populations: a randomised trial. Gut.2015 Sep (in press)

56.Liou JM, Bair MJ, Chen CC, Lee, YC, Chen MJ, Chen CC, Tseng CH, FangYJ, Lee JY, Yang TH, Luo JC, Wu JY, Chang WH, Chang CC, Chen CY,Chen PY, Shun CT, Hsu WF, Hung HW, Lin JT, Chang CY*, Wu MS
Levofloxacin sequential therapy versus levofloxacin triple therapy in thesecond line treatment of Helicobacter pylori: A randomized trial. Am JGastroenterol. 2016 Mar; 111(3):381-7

57.Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, ChenCC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY,Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY,El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and HelicobacterConsortium..
Concomitant, bismuth quadruple, and 14-day triple therapy inthe first-line treatment of Helicobacter pylori: a multicentre, open-label,randomised trial. Lancet. 2016 Nov 12;388(10058):2355-2365.

58.Wang WL, Chang IW, Chen CC, Chang CY, Lin JT, Mo LR, Wang HP, Lee CT.
The Spatial Predilection for Early Esophageal Squamous Cell Neoplasia: A"Hot Zone" for Endoscopic Screening and Surveillance. Medicine (Baltimore).2016 Apr;95(15):e3311.

59.Wang WL, Chang WL, Yang HB, Wang YC, Chang IW, Lee CT, Chang CY,Lin JT, Sheu BS.
Low disabled-2 expression promotes tumor progression anddetermines poor survival and high recurrence of esophageal squamous cellcarcinoma. Oncotarget. 2016 Mar 29.(in press)

60.Hsu YC, Mo LR, Chang CY, Wu MS, Kao JH, Wang WL, Yang TH, Wang CS,Chiang MF, Chen CC, Fang YJ, Hung HW, Wu CY, Lin JT. Association
Between Serum Level of Hepatitis B Surface Antigen at End of EntecavirTherapy and Risk of Relapse in E Antigen-Negative Patients. ClinGastroenterol Hepatol. 2016 Oct;14(10):1490-1498.

61.Wang WL, Wang YC, Chang CY, Lo JL, Kuo YH, Hwang TZ, Wang CC, MoLR, Lin JT, Lee CT.
Human papillomavirus infection on initiatingsynchronous esophageal neoplasia in patients with head and neck cancer.Laryngoscope. 2016 May;126(5):1097-102.

62.Wang WL, Chang IW, Chen CC, Chang WL, Chu YY, Wu PH, Tai WC, ChenPY, Hsieh PH, Chung CS, Chang CY, Lin JT, Wang HP, Lee CT.
Predictors forpostoperative esophageal stricture after balloon-based radiofrequency ablationfor early esophageal squamous neoplasia: a multicenter validation study.Therap Adv Gastroenterol. 2016 May;9(3):257-64.

63.Wang WL, Chang IW, Chen CC, Chang CY, Mo LR, Lin JT, Wang HP, Lee CT.
A case series on the use of circumferential radiofrequency ablation for earlyesophageal squamous neoplasias in patients with esophageal varices.Gastrointest Endosc. 2016 Jun 27. pii: S0016-5107(16)30329-7.

64.Tseng CM, Chen TB, Hsu YC, Chang CY, Lin JT, Mo LR.
Comparativeeffectiveness of nucleos(t)ide analogues in chronic hepatitis B patientsundergoing cytotoxic chemotherapy. Asia Pac J Clin Oncol.2016Dec;12(4):421-429.

65.Chou CK, Chang CY, Chang CC, Chang LC, Hsu WF, Chen CY, Wang HP,Chiu HM.
Controlled Dietary Restriction With a Prepackaged Low-ResidueDiet Before Colonoscopy Offers Better-Quality Bowel Cleansing and Allowsthe Use of a Smaller Volume of Purgatives: A Randomized Multicenter Trial.Dis Colon Rectum. 2016 Oct;59(10):975-83.

66.Liou JM, Chang CY*, Wu MS. Reply to Kim J.S. and Kim B.-W. Am J
Gastroenterol. 2016 Oct;111(10):1497-1498.

67.Tseng CM, Liao WC, Chang CY, Lee CT, Tseng CH, Hsu YC, Lin JT.
Incretin-based pharmacotherapy and risk of adverse pancreatic events in theethnic Chinese with diabetes mellitus: A population-based study in Taiwan.Pancreatology. 2017 Jan-Feb;17(1):76-82.

68.Chang CY, Lee LJ, Wang JD, Lee CT, Tai CM, Tang TQ, Lin JT.
Health-related quality of life in patients with Barrett's esophagus. Health QualLife Outcomes. 2016 Nov 14;14(1):158.

69.Chen CC, Hsu YC, Lee CT, Hsu CC, Tai CM, Wang WL, Tseng CH, Hsu CT,Lin JT, Chang CY*.
Central Obesity and H. pylori Infection Influence Risk ofBarrett's Esophagus in an Asian Population. PLoS One.2016 Dec9;11(12):e0167815.

70.Hsu YC, Mo LR, Chang CY, Wu MS, Yang TH, Kao JH, Chen CC, Tseng CH,Tai CM, Lin CW, Wu CY, Lin JT.
Serum viral load at the virological relapsepredicts subsequent clinical flares in chronic hepatitis B patients off entecavirtherapy.J Gastroenterol Hepatol. 2017 (in press).

會議報告部分:

1.Chang CY, et al. Health-Related Quality of Life in Barrett’s Esophagus. AsianPacific Digestive Week, Singapore, 2010

2.Chang CY, et al. Dynamic improvements in health-related quality of life afterbariatric surgery: A one year follow-up. Digestive Disease Week, New Orlean,2011

3.Chang CY, et al. Risk factors for Barrett’s esophagus in an ethnic Chinesepopulation. Digestive Disease Week, San Diego, 2012

4.Chang CY, et al. A prospective follow-up study for patients with Barrett’sesophagus in an ethnic Chinese cohort. Asian Pacific Digestive Week, Bangkok,2012

5.Chang CY, et al. Dynamic changes of health-related quality of life after pegylatedinterferon and ribavirin treatment for chronic hepatitis C. Digestive Disease Week,Orlando, 2013

6.Chang CY, et al. Lower dysplastic progression of Barrett’s esophagus inAsian population- an ethnic Chinese prospective cohort study. DigestiveDisease Week, Washington DC , 2015

7.Chang CY, et al. An endoscopic training program in validating a newclassification system of magnifying endoscopy with narrow band imaging forpredicting the invasion depths of superficial esophageal squamous cellcarcinomas. Digestive Disease Week, San Diego, 2016